News
AZN
68.31
-0.32%
-0.22
Astrazeneca (AZN) Could Be a Great Choice
NASDAQ · 12h ago
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen provides update on results of the Phase 2a trial for Tezspire in chronic obstructive pulmonary disease. Tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17%. The reduction was not statistically significant.
Benzinga · 1d ago
International Wide-Moat Stocks On Sale - The April 2024 Heat Map
As of April 16, there were 80 international wide-moat stocks meeting Morningstar's criteria. Only 17.7% of this group of stocks earned a 5-star valuation rating. The heat map of the most investable candidates is a good indicator of the best companies on sale. Morningstar lists 80 international Wide-Moat Stocks On Sale.
Seeking Alpha · 1d ago
J.P. Morgan outlines major European players flagging pricing power issues in earnings
J.P. Morgan outlines major European players flagging pricing power issues in earnings. The brokerage believes a likely softening in pricing will be a theme for the first quarter earnings season. Some major European companies have flagged pricing as an issue during analyst calls. J.p. Morgan believes earnings projections may keep declining in 2024.
Seeking Alpha · 2d ago
Deutsche Bank Upgrades AstraZeneca to Hold
Benzinga · 2d ago
VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'
Europe's 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. The "Magnificent 7" stocks in the US lead returns and headlines in Europe. The Magnificent 7 is a proxy for the Invesco QQQ and Europe's FTSE Europe ETF "VGK" In the past year, the Mag 7 has outperformed Europe's GRanOLAS.
Seeking Alpha · 2d ago
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca announces updated results from the TOPAZ-1 Phase 3 trial of Imfinzi in combination with chemotherapy for advanced biliary tract cancer. The company says the results are the longest survival follow-up ever reported for a Phase 3 study in this setting.
Benzinga · 2d ago
AstraZeneca Imfinzi long-term survival buoyed by new data
AstraZeneca's Imfinzi + chemotherapy led to long-term overall survival at three years in those with advanced biliary tract cancer. Updated follow-up data from a phase 3 trial found the combination reduced death risk by 26%. Results will be presented April 18 in Utah.
Seeking Alpha · 2d ago
ASHER BIO - FUNDING ROUND HAD PARTICIPATION FROM EXISTING INVESTORS AND ADDITIONAL NEW INVESTORS, INCLUDING ASTRAZENECA AND BRISTOL MYERS SQUIBB
Reuters · 2d ago
BUZZ-Top of the Street: AstraZeneca, Barry Callebaut, Ahold Delhaize, Voestalpine
Deutsche Bank raises AstraZeneca, Barry Callebaut, Ahold Delhaize, Voestalpine to "hold" from "sell" UBS raises Swiss chocolate maker Barry Calalbaut to "sell"; J.P. Morgan downgrades Austrian specialty steelmaker. Bernstein resumes coverage of Dutch supermarket group Ahold delhaize.
Reuters · 2d ago
AstraZeneca's Imfinzi Plus Chemotherapy Doubled Overall Survival Rate At Three Years For Patients With Advanced Biliary Tract Cancer In TOPAZ-1 Phase 3 Trial
Imfinzi plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone at three years. The median OS was 12.9 months for patients on the Imfinzi-based regimen and 11.3 months for chemotherapy alone. The study was published in the Journal of Clinical Oncology.
Benzinga · 2d ago
*AstraZeneca Target Raised to GBP105 From GBP95 by Deutsche Bank
Dow Jones · 2d ago
*AstraZeneca Raised to Hold From Sell by Deutsche Bank
Dow Jones · 2d ago
Weekly Report: what happened at AZN last week (0408-0412)?
Weekly Report · 3d ago
PRESS DIGEST- Financial Times - April 15
UK home insurers hit by surge in weather damage claims. SoftBank-backed UK digital bank Zopa turns a profit as it eyes an IPO. Britain's Treasury urged to reverse end of stamp-duty relief for multiple dwellings. AstraZeneca chair hits out at proxy advisers for inflicting 'serious harm' to UK.
Reuters · 4d ago
PRESS DIGEST-British Business - April 15
The Body Shop is seeking approval for a plan to reduce its tax bill when it returns to profitability. AstraZeneca chairman attacks proxy advisory groups for their stance on executive pay. Britain's homes and businesses to receive $6.05 billion in property insurance payouts in 2023.
Reuters · 4d ago
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Four exceptional growth stocks you'll regret not buying in the new Nasdaq bull market. The growth stock-fueled Nasdaq Composite has soared 57% since the beginning of 2023. Visa is in pole position to benefit from the U.S. Economy's long-term growth. PubMatic is positioned to benefit in the election year from political ad spend.
The Motley Fool · 4d ago
U.K. Top 40 Quality Dividend Stocks: Q2 2024
John Kingham has updated the list of the top 40 UK dividend stocks. The list ranks stocks based on their market cap and dividend yield alone. He is looking for quality dividend stocks with long track records of progressive dividend growth. The top 40 list now only includes stocks from the FTSE All-Share and AIM UK 50 indices.
Seeking Alpha · 6d ago
Peter Lynch Detailed Fundamental Analysis - AZN
NASDAQ · 6d ago
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
The European Medicines Agency has determined that there is no substantial evidence supporting a link between GLP-1 receptor agonists and suicidal or self-injurious thoughts and behaviors. The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLp-1 RAs.
Benzinga · 6d ago
More
Webull provides a variety of real-time AZN stock news. You can receive the latest news about Astrazeneca Plc through multiple platforms. This information may help you make smarter investment decisions.
About AZN
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.